If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Prometheus Biosciences, Inc. (RXDX)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). They leverage their proprietary precision medicine platform, Prometheus360, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, they are developing companion diagnostic tests designed to identify patients more likely to respond to their therapeutic candidates. They have generated a robust initial pipeline of therapeutic development programs for the treatment of IBD. Their lead product candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF)-like ligand 1A (TL1A), a target associated with both intestinal inflammation and fibrosis that was clinically validated in a third-party Phase 2a clinical trial in ulcerative colitis (UC). PRA023 has the potential to substantially improve outcomes for moderate-to-severe IBD patients who are predisposed to increased TL1A expression. They are developing PRA023 for the treatment of UC and Crohn’s disease (CD), and initiated a Phase 1a clinical trial in normal healthy volunteers in December 2020. Their goal is to revolutionize the treatment of IBD with a precision medicine approach for patients with significant unmet medical needs.
Mark C. McKenna Keith W. Marshall
Employees Founded
33 2016


Address: 9410 Carroll Park Drive San Diego, California 92121

Telephone: 858-824-0895

Web page:

IPO information

First Trade Date 3/12/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $16.00-$18.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.4
Shares Revised (MM) 10
Expected offer amount (MM) $125.8
Realized offer amount(MM) $190

Financial Data (last reporting year)

Market Cap (MM) $689.63
Revenues (MM) $1.2
Net Income (Loss) (MM) $-37.14


What do you think will happen with the RXDX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: SVB Leerink

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
SVB Leerink/ Credit Suisse/ Stifel/ Guggenheim Securities

Sector: Healthcare

Tweets about $RXDX

Tweets volume:

RT volume:


Google Trends Stats